JP2025163134A5 - - Google Patents
Info
- Publication number
- JP2025163134A5 JP2025163134A5 JP2025128508A JP2025128508A JP2025163134A5 JP 2025163134 A5 JP2025163134 A5 JP 2025163134A5 JP 2025128508 A JP2025128508 A JP 2025128508A JP 2025128508 A JP2025128508 A JP 2025128508A JP 2025163134 A5 JP2025163134 A5 JP 2025163134A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutically acceptable
- isovaleric acid
- acceptable salt
- palm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895201P | 2019-09-03 | 2019-09-03 | |
| US62/895,201 | 2019-09-03 | ||
| US202062983515P | 2020-02-28 | 2020-02-28 | |
| US62/983,515 | 2020-02-28 | ||
| US202063020945P | 2020-05-06 | 2020-05-06 | |
| US63/020,945 | 2020-05-06 | ||
| US202063059747P | 2020-07-31 | 2020-07-31 | |
| US63/059,747 | 2020-07-31 | ||
| JP2022540618A JP7831841B2 (ja) | 2019-09-03 | 2020-09-03 | コンジュゲートされたヘプシジン模倣物 |
| PCT/US2020/049244 WO2021046246A1 (en) | 2019-09-03 | 2020-09-03 | Conjugated hepcidin mimetics |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540618A Division JP7831841B2 (ja) | 2019-09-03 | 2020-09-03 | コンジュゲートされたヘプシジン模倣物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025163134A JP2025163134A (ja) | 2025-10-28 |
| JP2025163134A5 true JP2025163134A5 (enExample) | 2026-05-15 |
Family
ID=74681239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540618A Active JP7831841B2 (ja) | 2019-09-03 | 2020-09-03 | コンジュゲートされたヘプシジン模倣物 |
| JP2025128508A Pending JP2025163134A (ja) | 2019-09-03 | 2025-07-31 | コンジュゲートされたヘプシジン模倣物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540618A Active JP7831841B2 (ja) | 2019-09-03 | 2020-09-03 | コンジュゲートされたヘプシジン模倣物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220372099A1 (enExample) |
| EP (2) | EP4706671A3 (enExample) |
| JP (2) | JP7831841B2 (enExample) |
| KR (1) | KR20220075343A (enExample) |
| CN (1) | CN114729022A (enExample) |
| AU (2) | AU2020343328B2 (enExample) |
| BR (1) | BR112022003999A2 (enExample) |
| CA (1) | CA3152789A1 (enExample) |
| DK (1) | DK4025592T3 (enExample) |
| ES (1) | ES3058577T3 (enExample) |
| FI (1) | FI4025592T3 (enExample) |
| IL (1) | IL291030A (enExample) |
| MX (1) | MX2022002633A (enExample) |
| PH (1) | PH12022550510A1 (enExample) |
| PL (1) | PL4025592T3 (enExample) |
| WO (1) | WO2021046246A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2022212696A1 (en) * | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3220871A1 (en) * | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| US20250170216A1 (en) * | 2022-02-02 | 2025-05-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
| WO2024011188A1 (en) * | 2022-07-07 | 2024-01-11 | Protagonist Therapeutics, Inc. | Combination therapy for treatment of iron overload diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| US7094785B1 (en) * | 2002-12-18 | 2006-08-22 | Cornell Research Foundation, Inc. | Method of treating polycythemia vera |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| KR20170002414A (ko) * | 2014-04-07 | 2017-01-06 | 멀겐져 바이오텍, 아이엔씨. | 헵시딘 모방 펩티드 및 그 용도 |
| AU2015279571A1 (en) * | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| WO2017068089A2 (en) | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| CA3009834A1 (en) * | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| AU2017324446A1 (en) | 2016-09-06 | 2019-03-28 | La Jolla Pharmceutical Company | Methods of treating iron overload |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2020
- 2020-09-03 US US17/639,138 patent/US20220372099A1/en not_active Abandoned
- 2020-09-03 KR KR1020227011086A patent/KR20220075343A/ko active Pending
- 2020-09-03 CN CN202080076351.4A patent/CN114729022A/zh active Pending
- 2020-09-03 WO PCT/US2020/049244 patent/WO2021046246A1/en not_active Ceased
- 2020-09-03 CA CA3152789A patent/CA3152789A1/en active Pending
- 2020-09-03 AU AU2020343328A patent/AU2020343328B2/en active Active
- 2020-09-03 BR BR112022003999A patent/BR112022003999A2/pt unknown
- 2020-09-03 EP EP25211675.1A patent/EP4706671A3/en active Pending
- 2020-09-03 PH PH1/2022/550510A patent/PH12022550510A1/en unknown
- 2020-09-03 MX MX2022002633A patent/MX2022002633A/es unknown
- 2020-09-03 DK DK20860676.4T patent/DK4025592T3/da active
- 2020-09-03 JP JP2022540618A patent/JP7831841B2/ja active Active
- 2020-09-03 FI FIEP20860676.4T patent/FI4025592T3/fi active
- 2020-09-03 US US17/011,844 patent/US20210061872A1/en active Pending
- 2020-09-03 ES ES20860676T patent/ES3058577T3/es active Active
- 2020-09-03 EP EP20860676.4A patent/EP4025592B1/en active Active
- 2020-09-03 PL PL20860676.4T patent/PL4025592T3/pl unknown
-
2022
- 2022-03-01 IL IL291030A patent/IL291030A/en unknown
-
2025
- 2025-07-31 JP JP2025128508A patent/JP2025163134A/ja active Pending
-
2026
- 2026-06-29 AU AU2026205090A patent/AU2026205090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546878A5 (enExample) | ||
| JP2024520861A5 (enExample) | ||
| JP6279626B2 (ja) | エンドモルフィンのμオピオイド受容体アゴニスト類似体 | |
| JP2025163134A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| EP0181001B1 (en) | Polypeptide, a process for preparing the same, a pharmaceutical composition containing said polypeptide as well as the use thereof | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| EP0389180B1 (en) | Peptides and their use in therapy | |
| US11414474B2 (en) | Long-acting adrenomedullin derivatives | |
| ES2523375T3 (es) | Antagonistas de GH-RH fluorados | |
| IL192046A (en) | Intact and peptide intestinal fragments and methods of use | |
| US8227405B2 (en) | Fluorinated GHRH antagonists | |
| US20070042950A1 (en) | Antagonistic analogs of gh rh (2003) | |
| WO2024011188A1 (en) | Combination therapy for treatment of iron overload diseases | |
| JPH0753591A (ja) | 胃腸運動活性を抑制するモチリン類似ポリペプチド | |
| WO1991010681A1 (en) | Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues | |
| EP1320378A2 (en) | Improved protocol for paracentesis | |
| KR100240434B1 (ko) | 구조적으로 변형된 혈관작용성 소장 펩티드(vip)의 유도체 및 이를 함유한 제약 조성물 | |
| US6426330B1 (en) | Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it | |
| CA2405704C (en) | Bombesin analogs for treatment of cancer | |
| JPH0770178A (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| CA1338302C (en) | Therapeutic octapeptide somatostatin analogs | |
| US8691942B2 (en) | N- and C- terminal substituted antagonistic analogs of GH-RH | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| CA2385910A1 (en) | Somatostatin analogs for the treatment of cancer | |
| JPH03502336A (ja) | 魚のｃｒｆ |